Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Autophagy in thyroid cancer: Immune suppression and drug resistance.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy·2026
Same author

Recalibration of the European Kidney Function Consortium eGFR Equation for the Indian Population.

Kidney international reports·2026
Same author

Beyond the brain barrier: Hybrid nanoparticles orchestrating intelligent neuro-theranostics.

Advances in colloid and interface science·2026
Same author

Neuroprotective role of cyanidin in Alzheimer's and Parkinson's disease: current insights and the road ahead.

Inflammopharmacology·2026
Same author

Unwrapping the Dodecaborane Core: Structure, Electronic Properties, and Chemical Reactivity Across the Complete [B<sub>12</sub>I<sub><i>n</i></sub>]<sup>-</sup> Series (<i>n</i> = 11-1).

Journal of the American Chemical Society·2026
Same author

Changes in childhood cancer incidence rates and trends in Canada (2001-2023): Results from the Cancer in Young People in Canada surveillance program.

Cancer epidemiology·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

药物开发 药物开发

Sambita Panda1, Sachin Kumar Singh2, Bushra Bashir2

  • 1Lovely Professional University, Phagwara, Punjab, India.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括
此摘要是机器生成的。

一种新型的自我乳化药物输送系统 (SNEDDS) 增强了用于阿尔茨海默病 (AD) 治疗的伊索哈姆尼丁 (IH) 的输送. 这改善了认知功能,并减少了老鼠模型中的关键AD生物标志物.

更多相关视频

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

相关实验视频

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

科学领域:

  • 神经科学是一个神经科学.
  • 药理学 药理学是指药理学的学科.
  • 生物化学 生物化学

背景情况:

  • 阿尔茨海默病 (AD) 是一种神经退行性疾病,其特征是粉样斑块,团,神经炎症和氧化应激.
  • 伊索拉姆尼丁 (IH) 通过抑制关键炎症途径,表现出对AD的神经保护性质.
  • 溶解性,生物可用性和血脑屏障 (BBB) 透率差,限制了IH的治疗效果.

研究的目的:

  • 开发一种含有 Isorhamnetin (IH) 的自我乳化药物输送系统 (SNEDDS),以克服输送方面的挑战.
  • 在阿尔茨海默氏病模型中评估IH载SNEDDS的神经保护作用和治疗潜力.

主要方法:

  • 开发了一种优化的IH载荷SNEDDS配方,并根据颗粒大小,PDI,zeta潜力和药物载荷进行了表征.
  • 使用莫里斯水迷宫测试的药理学研究评估了老鼠的认知和运动功能.
  • 生物化学分析测量了阿尔茨海默病的标志物,包括乙胆酶 (AChE) 水平,β-粉样蛋白,氧化应激和神经炎症.

主要成果:

  • 优化的IH-SNEDDS配方表现出有利的特征,包括滴粒大小为59.46nm,PDI为0.3,泽塔电位为19mV,药物负载为96%.
  • 在接受高剂量IH-SNEDDS治疗的老鼠中,观察到认知和运动功能的显著改善.
  • 该配方有效降低了ACHE水平,粉样β沉积,氧化应激和神经炎症,表明了治疗效果.

结论:

  • IH装载的SNEDDS代表了管理阿尔茨海默病的有前途的治疗策略.
  • 开发的SNEDDS配方增强了Isorhamnetin在治疗AD的输送和疗效.
  • 这种方法解决了IH的局限性,提供了改善的生物可用性和BBB透以进行神经保护.